AAPL325.28+9.94 (+3.15%) ▲|ABBV253.57+2.66 (+1.06%) ▲|ABT103.46-1.77 (-1.68%) ▼|ACN177.87+2.07 (+1.18%) ▲|ADBE249.01-5.85 (-2.30%) ▼|AMAT456.75-12.10 (-2.58%) ▼|AMD505.31-15.79 (-3.03%) ▼|AMGN382.46-8.82 (-2.25%) ▼|AMT172.51-2.92 (-1.66%) ▼|AMZN251.64-0.76 (-0.30%) ▼|AVGO361.91-2.47 (-0.68%) ▼|AXP320.62-1.18 (-0.37%) ▼|BA204.88-1.55 (-0.75%) ▼|BAC62.50-0.18 (-0.28%) ▼|BKNG174.23+0.80 (+0.46%) ▲|BLK1,062.91-9.12 (-0.85%) ▼|BMY63.92-0.50 (-0.77%) ▼|BNY162.53+0.02 (+0.01%) ▲|BRK-B506.43-0.29 (-0.06%) ▼|C138.20+0.40 (+0.29%) ▲|CAT803.92-11.64 (-1.43%) ▼|CL87.93-0.10 (-0.11%) ▼|CMCSA25.19+0.60 (+2.44%) ▲|COF207.00-3.86 (-1.83%) ▼|COP137.45+0.92 (+0.67%) ▲|COST901.51-1.09 (-0.12%) ▼|CRM242.83-1.33 (-0.54%) ▼|CSCO107.85-1.58 (-1.44%) ▼|CVS95.44+0.06 (+0.06%) ▲|CVX213.10-0.72 (-0.33%) ▼|DE677.02-0.20 (-0.03%) ▼|DHR201.03-3.83 (-1.87%) ▼|DIS105.12+0.94 (+0.90%) ▲|DUK119.59-0.85 (-0.70%) ▼|EMR147.71-2.63 (-1.75%) ▼|FDX311.71+2.52 (+0.82%) ▲|GD354.24+1.57 (+0.45%) ▲|GE323.54-1.88 (-0.58%) ▼|GEV923.32-27.72 (-2.91%) ▼|GILD144.92-0.73 (-0.50%) ▼|GM85.87+2.11 (+2.52%) ▲|GOOG330.30+1.92 (+0.58%) ▲|GOOGL332.68+2.03 (+0.61%) ▲|GS1,017.64-11.14 (-1.08%) ▼|HD305.04-5.41 (-1.74%) ▼|HON201.98-2.95 (-1.44%) ▼|IBM233.73-6.21 (-2.59%) ▼|INTC101.00-5.24 (-4.93%) ▼|INTU311.98-1.96 (-0.63%) ▼|ISRG360.87+7.63 (+2.16%) ▲|JNJ266.59-0.49 (-0.18%) ▼|JPM353.02-1.69 (-0.48%) ▼|KO88.00+0.45 (+0.51%) ▲|LIN461.04-5.62 (-1.20%) ▼|LLY1,123.98-0.23 (-0.02%) ▼|LMT528.40+3.94 (+0.75%) ▲|LOW196.31-2.29 (-1.15%) ▼|LRCX299.98-15.86 (-5.02%) ▼|MA564.61-2.89 (-0.51%) ▼|MCD252.96-0.52 (-0.21%) ▼|MDLZ62.28-0.14 (-0.22%) ▼|MDT91.62-0.27 (-0.29%) ▼|META643.23-10.47 (-1.60%) ▼|MMM162.74-1.66 (-1.01%) ▼|MO68.57+0.68 (+1.00%) ▲|MRK144.69-2.85 (-1.93%) ▼|MS213.33-2.02 (-0.94%) ▼|MSFT490.76-0.90 (-0.18%) ▼|MU981.93-45.84 (-4.46%) ▼|NEE82.68+0.03 (+0.04%) ▲|NFLX75.86-0.17 (-0.22%) ▼|NKE36.59-0.76 (-2.03%) ▼|NOW131.14+0.03 (+0.02%) ▲|NVDA218.38-5.29 (-2.37%) ▼|ORCL153.94-7.69 (-4.76%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.53-0.26 (-0.92%) ▼|PG143.06+0.42 (+0.30%) ▲|PLTR165.70-3.83 (-2.26%) ▼|PM189.55+3.84 (+2.07%) ▲|QCOM177.81+1.41 (+0.80%) ▲|RTX197.41-0.14 (-0.07%) ▼|SBUX99.65-0.39 (-0.39%) ▼|SCHW106.74+0.20 (+0.18%) ▲|SO87.91-0.44 (-0.49%) ▼|SPG205.94+1.41 (+0.69%) ▲|T25.53+0.38 (+1.49%) ▲|TMO602.65-3.05 (-0.50%) ▼|TMUS176.76-0.58 (-0.33%) ▼|TSLA363.84-3.98 (-1.08%) ▼|TXN259.47-2.12 (-0.81%) ▼|UBER72.45+1.37 (+1.93%) ▲|UNH390.92-2.14 (-0.54%) ▼|UNP284.23-0.52 (-0.18%) ▼|UPS100.08+0.86 (+0.86%) ▲|USB62.01-0.11 (-0.17%) ▼|V366.59-0.80 (-0.22%) ▼|VZ49.92+0.18 (+0.36%) ▲|WFC88.94-0.74 (-0.82%) ▼|WMT105.89+0.06 (+0.05%) ▲|XOM165.42+1.19 (+0.72%) ▲|AAPL325.28+9.94 (+3.15%) ▲|ABBV253.57+2.66 (+1.06%) ▲|ABT103.46-1.77 (-1.68%) ▼|ACN177.87+2.07 (+1.18%) ▲|ADBE249.01-5.85 (-2.30%) ▼|AMAT456.75-12.10 (-2.58%) ▼|AMD505.31-15.79 (-3.03%) ▼|AMGN382.46-8.82 (-2.25%) ▼|AMT172.51-2.92 (-1.66%) ▼|AMZN251.64-0.76 (-0.30%) ▼|AVGO361.91-2.47 (-0.68%) ▼|AXP320.62-1.18 (-0.37%) ▼|BA204.88-1.55 (-0.75%) ▼|BAC62.50-0.18 (-0.28%) ▼|BKNG174.23+0.80 (+0.46%) ▲|BLK1,062.91-9.12 (-0.85%) ▼|BMY63.92-0.50 (-0.77%) ▼|BNY162.53+0.02 (+0.01%) ▲|BRK-B506.43-0.29 (-0.06%) ▼|C138.20+0.40 (+0.29%) ▲|CAT803.92-11.64 (-1.43%) ▼|CL87.93-0.10 (-0.11%) ▼|CMCSA25.19+0.60 (+2.44%) ▲|COF207.00-3.86 (-1.83%) ▼|COP137.45+0.92 (+0.67%) ▲|COST901.51-1.09 (-0.12%) ▼|CRM242.83-1.33 (-0.54%) ▼|CSCO107.85-1.58 (-1.44%) ▼|CVS95.44+0.06 (+0.06%) ▲|CVX213.10-0.72 (-0.33%) ▼|DE677.02-0.20 (-0.03%) ▼|DHR201.03-3.83 (-1.87%) ▼|DIS105.12+0.94 (+0.90%) ▲|DUK119.59-0.85 (-0.70%) ▼|EMR147.71-2.63 (-1.75%) ▼|FDX311.71+2.52 (+0.82%) ▲|GD354.24+1.57 (+0.45%) ▲|GE323.54-1.88 (-0.58%) ▼|GEV923.32-27.72 (-2.91%) ▼|GILD144.92-0.73 (-0.50%) ▼|GM85.87+2.11 (+2.52%) ▲|GOOG330.30+1.92 (+0.58%) ▲|GOOGL332.68+2.03 (+0.61%) ▲|GS1,017.64-11.14 (-1.08%) ▼|HD305.04-5.41 (-1.74%) ▼|HON201.98-2.95 (-1.44%) ▼|IBM233.73-6.21 (-2.59%) ▼|INTC101.00-5.24 (-4.93%) ▼|INTU311.98-1.96 (-0.63%) ▼|ISRG360.87+7.63 (+2.16%) ▲|JNJ266.59-0.49 (-0.18%) ▼|JPM353.02-1.69 (-0.48%) ▼|KO88.00+0.45 (+0.51%) ▲|LIN461.04-5.62 (-1.20%) ▼|LLY1,123.98-0.23 (-0.02%) ▼|LMT528.40+3.94 (+0.75%) ▲|LOW196.31-2.29 (-1.15%) ▼|LRCX299.98-15.86 (-5.02%) ▼|MA564.61-2.89 (-0.51%) ▼|MCD252.96-0.52 (-0.21%) ▼|MDLZ62.28-0.14 (-0.22%) ▼|MDT91.62-0.27 (-0.29%) ▼|META643.23-10.47 (-1.60%) ▼|MMM162.74-1.66 (-1.01%) ▼|MO68.57+0.68 (+1.00%) ▲|MRK144.69-2.85 (-1.93%) ▼|MS213.33-2.02 (-0.94%) ▼|MSFT490.76-0.90 (-0.18%) ▼|MU981.93-45.84 (-4.46%) ▼|NEE82.68+0.03 (+0.04%) ▲|NFLX75.86-0.17 (-0.22%) ▼|NKE36.59-0.76 (-2.03%) ▼|NOW131.14+0.03 (+0.02%) ▲|NVDA218.38-5.29 (-2.37%) ▼|ORCL153.94-7.69 (-4.76%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.53-0.26 (-0.92%) ▼|PG143.06+0.42 (+0.30%) ▲|PLTR165.70-3.83 (-2.26%) ▼|PM189.55+3.84 (+2.07%) ▲|QCOM177.81+1.41 (+0.80%) ▲|RTX197.41-0.14 (-0.07%) ▼|SBUX99.65-0.39 (-0.39%) ▼|SCHW106.74+0.20 (+0.18%) ▲|SO87.91-0.44 (-0.49%) ▼|SPG205.94+1.41 (+0.69%) ▲|T25.53+0.38 (+1.49%) ▲|TMO602.65-3.05 (-0.50%) ▼|TMUS176.76-0.58 (-0.33%) ▼|TSLA363.84-3.98 (-1.08%) ▼|TXN259.47-2.12 (-0.81%) ▼|UBER72.45+1.37 (+1.93%) ▲|UNH390.92-2.14 (-0.54%) ▼|UNP284.23-0.52 (-0.18%) ▼|UPS100.08+0.86 (+0.86%) ▲|USB62.01-0.11 (-0.17%) ▼|V366.59-0.80 (-0.22%) ▼|VZ49.92+0.18 (+0.36%) ▲|WFC88.94-0.74 (-0.82%) ▼|WMT105.89+0.06 (+0.05%) ▲|XOM165.42+1.19 (+0.72%) ▲|
30.6 C
New York
Thursday, September 10, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1releasesmarket

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)

TORONTO, July 23, 2025 /CNW/ - Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British...

Hydrasphere Plus Launches Comprehensive Skincare System Targeting Texture, Muscle Tone, and Collagen Renewal

Boca Raton, FL, July 23, 2025 (GLOBE NEWSWIRE) -- Hydrasphere Plus, a Florida-based skincare innovator, has officially launched a pioneering three-pillar system designed to transform the science of facial health. Built on decades of dermatological research and cosmetic formulation expertise, the new Hydrasphere Plus system uniquely targets skin texture, facial muscle tone, and collagen production—three biological pillars essential to long-term skin vitality.

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential

SAN DIEGO and CALGARY, AB, July 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for...

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential

SAN DIEGO and CALGARY, AB, July 23, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for...

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid...

Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for...

Modified Cassava Starch Market worth $3.37 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 23, 2025 /PRNewswire/ -- According to MarketsandMarkets™, The modified cassava starch market is projected to grow from USD 2.52 billion in...

Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons

BEACHWOOD, Ohio, July 23, 2025 /PRNewswire/ -- Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells...

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Compounds developed through collaboration with Variational AI show targeted activity 
Compounds developed through collaboration with Variational AI show targeted activity

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers